Eyenovia (EYEN) said Friday that Avenue Capital Management has agreed to support a potential restructuring of Eyenovia's loan and security agreement, and defer principal and interest payments on its outstanding debt until the end of February 2025.
The ophthalmic technology company also said it is taking additional actions to cut personnel-related costs by more than 70%.
The company previously said it is considering various restructuring moves aimed at maximizing shareholder value, reducing expenses, and evaluating its strategic options, which could include a business combination, reverse merger, asset sales, or a combination of the three.
Shares of Eyenovia were up more than 11% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.